New quinoline / chalcone hybrids containing 1,2,4-triazole moiety have been designed, synthesized and their structures elucidated and confirmed by various spectroscopic techniques. The designed compounds showed moderate to good activity on different NCI 60 cell lines in a single-dose assay with a growth inhibition rate ranging from 50% to 94%. Compounds 7b, 7d, 9b, and 9d were the most active compounds in most cancer cell lines with a growth inhibition percent between 77% and 94%. Newly synthesized hybrids were evaluated for their anti-proliferative activity against a panel of four human cancer cell lines. Compounds 7a, 7b, 9a, 9b, and 9d showed promising antiproliferative activities. These compounds were further tested for their inhibitory potency against EGFR and BRAF^V600E kinases with erlotinib as a reference drug. The molecular docking study of compounds 7a, 7b, 9a, 9b, and 9d revealed nice fitting into the active site of EGFR and BRAF^V600E kinases. Compounds 7b, 9b, and 9d displayed the highest binding affinities and similar binding pattern to those of erlotinib.

已经设计、合成了含有 1,2,4-三唑部分的新型喹啉/查耳酮杂化物，并通过各种光谱技术阐明和确认了它们的结构。设计的化合物在单剂量试验中对不同的 NCI 60 细胞系显示出中等至良好的活性，生长抑制率为 50% 至 94%。化合物7b、7d、9b和9d是大多数癌细胞系中活性最强的化合物，其生长抑制百分比在 77% 和 94% 之间。评估了新合成的杂交体对一组四种人类癌细胞系的抗增殖活性。化合物7a、7b、9a、9b和9d显示出有希望的抗增殖活性。以厄洛替尼作为参考药物，进一步测试了这些化合物对 EGFR 和 BRAF ^V600E激酶的抑制效力。化合物7a、7b、9a、9b和9d的分子对接研究表明，它们非常适合 EGFR 和 BRAF ^V600E激酶的活性位点。化合物7b、9b和9d显示出最高的结合亲和力和与厄洛替尼相似的结合模式。